Pathogenic variants in RBM20 cause an aggressive form of heart disease. van den Hoogenhof et al. show that overactivated CAMK2D drives this disease, and that pharmacological CAMK2D inhibition is a promising therapeutic approach in patients with RBM20 cardiomyopathy.
- Maarten M. G. van den Hoogenhof
- Javier Duran
- Johannes Backs